CureLab Oncology is a biotechnology company developing new anti-cancer biologics. CureLab Oncology is committed to creating a family of revolutionary therapies for oncology patients in order to help prolong their lives.
CureLab Oncology's lead product, Elenagen™, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen™ reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.
The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen™. The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients. Based on these successful results, we initiated Phase II Clinical Trials outside of the United States, and are now preparing Phase II Clinical Trials within the US.
Company Details
- Employees
- 16
- Founded
- -
- Address
- Boston, Massachusetts 02138, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- curelab.com
- Keywords
- IT Consulting.
- HQ
- Boston, Massachusetts
Curelab Oncology Questions
Curelab Oncology's website is curelab.com
Curelab Oncology's LinkedIn profile is https://www.linkedin.com/company/cure-lab
Curelab Oncology has
16 employees.
View email and phone details for 16
employees at Curelab Oncology.
Curelab Oncology's industry is
Biotechnology Research
Curelab Oncology's top competitors are
Curelab Veterinary,
Medici Therapeutics,
Remote Home Check,
Digostics,
Cellanyx,
Bullpen,
Zea Biosciences,
Aging (Aging-Us),
Empath Biosciences,
The Health Pals® Company.
Curelab Oncology's categories are Biotechnology Research
Curelab Oncology's founding year is 2000
